MPA and MIA collaboration
7 November 2019
In a boost for melanoma patients across the country, Melanoma Patients Australia and Melanoma Institute Australia have announced a new multi-year agreement to provide enhanced support services for patients nationally. The agreement was announced at a Melanoma Information Forum held in Sydney, jointly hosted by both organisations. The forum detailed updates on treatments, surgery and strategies for living well and included expert advice from MIA Co-Medical Directors Professor Georgina Long and Professor Richard Scolyer.
The new MPA/MIA agreement will focus on:
- Introduction of a Tele Health Nurse Pilot Program to provide better access of services for melanoma patients
- Increased capacity and expertise of MPA’s Peer to Peer volunteer facilitators and volunteer support staff
- Enhanced face to face support groups within NSW and integration of these into MPA’s national support network
- Joint involvement in events including patient information sessions and MIA’s national Melanoma March campaign.
‘Both organisations look forward to partnering more closely to deliver enhanced support services to melanoma patients nationally,’ said Matthew Browne, CEO of Melanoma Institute Australia.
‘We are very excited and proud to be working with the incredible team at Melanoma Institute Australia,’ said Victoria Beedle, CEO of Melanoma Patients Australia. ‘MIA’s goal is zero deaths from melanoma achieved through research into new and exciting treatments for patients. With survival rates continuing to improve, the need for this collaboration to strengthen the Support Services available to our patients and families, is, thankfully, even greater. With this partnership we will achieve national synergies and strength from our collective efforts to raise awareness of melanoma in the community.’
Congratulations to our Conjoint Medical Directors, Professor Georgina Long and Professor Richard Scolyer, who have today been announced as Fellows of the Australian Academy of Health and Medical Sciences.
New research shows potentially deadly UV damage can appear decades earlier than you think.
Early lymph node check is saving lives in melanoma patients
We are pleased to announce that A/Prof Anne Cust is the new President of the Australasian Epidemiological Association.
More than $3.5 million in competitive funding grants have been awarded to MIA's researchers.
The ESMO conference provided a platform for announcing a number of key melanoma research findings - including practice-changing research from MIA.
Australian researchers have successfully trialled a combination of new treatments to prevent melanoma from spreading to distant organs.
A new treatment that combines an antibody with a cancer-killing virus improves outcomes for patients with advanced melanoma, an international clinical trial has shown.
It feels like groundhog day - another reality TV show, another batch of blatantly sunburnt contestants.
Wouldn’t it be great if your doctor could know if you would respond to treatment before you even had it?
In our latest research update we showcase research in survival estimates, uncover biomarkers, and reveal practice-changing research in surgery and medical oncology.
Senior Clinical Trial Coordinators, like Sarah Lane, support melanoma patients throughout the clinical trial process.
Melanomas are often hard to differentiate from moles. But new technology is helping to improve accuracy of diagnosis.
We are excited to announce that SunSense will proudly be an official supporter of Melanoma Institute Australia. SunSense is an Australian, family owned business.
Five years ago Julie Randall was diagnosed with melanoma and was given months to live. The melanoma had spread throughout her body. The doctors said it was incurable and she’d be lucky if she survived the next nine months. Julie, a patient at Melanoma Institute Australia under Professor Georgina Long was placed on an experimental drug trial. To watch the entire program, visit 9now.com or click here.
Meet our latest Surgical Oncology Fellow, Eva Nagy, to find out more about life as a surgical oncologist, why she came to MIA and what she hopes to achieve.
Melanoma research at ASCO this year focussed on the more precise use of current treatments to ensure optimal treatment for each patient.
MIA recently demonstrated that reflectance confocal microscopy is a useful tool in the clinic to diagnose suspicious-looking lesions in the mouth.